The G-quadruplex-interactive molecule BRACO-19 inhibits tumor growth, consistent with telomere targeting and interference with telomerase function

Cancer Research

Volumn 65, Issue 4, 2005, Pages 1489-1496

  Burger, Angelika M ^a,c   Dai, Fangping ^a   Schultes, Christoph M ^b   Reszka, Anthony P ^b   Moore, Michael J ^b   Double, John A ^d   Neidle, Stephen ^b,e  

^a Institute for Experimental Oncology   (Germany)

^b IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^c SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^d UNIVERSITY OF BRADFORD   (United Kingdom)

^e UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3,6,9 TRISUBSTITUTED ACRIDINE COMPOUND; ACRIDINE DERIVATIVE; DNA; TELOMERASE; TELOMERASE INHIBITOR; TELOMERASE REVERSE TRANSCRIPTASE; UBIQUITIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER REGRESSION; CATALYSIS; COMPLEX FORMATION; CYTOPLASM; DNA PROTEIN COMPLEX; DNA STRUCTURE; DNA SYNTHESIS; ENZYME INHIBITION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MITOSIS RATE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DNA BINDING; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; SENESCENCE; TELOMERE; TUMOR CELL LINE; TUMOR GROWTH; TUMOR XENOGRAFT; UTERUS CARCINOMA;

ACRIDINES; ANIMALS; CELL LINE, TUMOR; CELL NUCLEUS; CYTOPLASM; DNA; DNA, SINGLE-STRANDED; DNA-BINDING PROTEINS; FEMALE; GUANINE; HUMANS; MICE; MICE, NUDE; TELOMERASE; TELOMERE; UBIQUITIN; UTERINE NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 13944272246     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-2910     Document Type: Article

References (50)

1. Kim NW, Piatyszek MA, Prowse KR, et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994;266:2011-5.
2. Bryan TM, Cech TR. Telomerase and the maintenance of chromosome ends. Curr Opin Cell Biol 1999;11:318-24.
3. Greider CW, Blackburn EH. Identification of a specific telomere terminal transferase activity in Tetrahymena extracts. Cell 1985;43:405-13.
4. Blackburn EH. Switching and signaling at the telomere. Cell 2001;106:661-73.
5. Li GZ, Eller MS, Firoozabadi R, Gilchrest BA. Evidence that exposure of the telomere 3′ overhang sequence induces senescence. Proc Natl Acad Sci U S A 2003;100:527-31.
6. 2/M cell cycle arrest in Saccharomyces cerevisiae. J Biol Chem 2003;278:9318-21.
7. Takai H, Smogorzewska A, de Lange T. DNA damage foci at dysfunctional telomeres. Curr Biol 2003;13:1549-56.
8. d'Adda di Fagagna F, Reaper PM, Clay-Farrace L, et al. A DNA damage checkpoint response in telomere-initiated senescence. Nature 2003;426:194-8.
9. Hahn WC, Stewart SA, Brooks MW, et al. Inhibition of telomerase limits the growth of human cancer cells. Nature Medicine 1999;10:1164-70.
10. Zhang X, Mar V, Zhou W, Harrington L, Robinson MO. Telomere shortening and apoptosis in telomerase-inhibited human tumor cells. Genes Dev 1999;13:2388-99.
11. Herbert BS, Pitts AE, Baker SI, et al. Inhibition of human telomerase in immortal human cells leads to progressive telomere shortening and cell death. Proc Natl Acad Sci U S A 1999;96:14276-81.
12. Hahn WC, Counter CM, Lundberg AS, Beijersbergen RL, Brooks MW, Weinberg RA. Creation of human tumour cells with defined genetic elements. Nature 1999;400:464-8.
13. Shay JW, Wright WE. Telomerase: a target for cancer therapeutics. Cancer Cell 2002;2:257-65.
14. Mergny J-L, Riou J-F, Maillet P, Teulade-Fichou M-P, Gilson E. Natural and pharmacological regulation of telomerase. Nucleic Acids Res 2002;30:839-65.
15. Rezler EM, Bearss DJ, Hurley LH. Telomeres and telomerases as drug targets. Curr Opin Pharmacol 2002;2:415-23.
16. Neidle S, Parkinson GN. Telomere maintenance as a target for anticancer drug discovery. Nature Rev Drug Discovery 2002;1:383-93.
17. Vonderheide RH, Domchek SM, Schultze JL, et al. Vaccination of cancer patients against telomerase induces functional antitumor CD8+ T lymphocytes. Clin Cancer Res 2004;10:828-39.
18. Hemann MT, Strong MA, Hao LY, Greider CW. The shortest telomere, not average telomere length, is critical for cell viability and chromosome stability. Cell 2001;107:67-77.
19. Sun D, Thompson B, Cathers BE, et al. Inhibition of human telomerase by a G-quadruplex-interactive compound. J Med Chem 1997;40:2113-6.
20. Wright WE, Tesmer VM, Huffman KE, Levene SD, Shay JW. Normal human chromosomes have long G-rich telomeric overhangs at one end. Genes Dev 1997;11:2801-9.
21. Parkinson GN, Lee MPH, Neidle S. Crystal structure of parallel quadruplexes from human telomeric DNA. Nature 2002;417:876-80.
22. Zahler AM, Williamson JR, Cech TR, Prescott DM. Inhibition of telomerase by G-quartet DNA structures. Nature 1991;350:718-20.
23. Riou J-F, Guittat L, Mailliet P, et al. Cell senescence and telomere shortening induced by a new series of specific G-quadruplex DNA ligands. Proc Natl Acad Sci U S A 2002;2672-7.
24. Shammas MA, Reis RJ, Li C, et al. Telomerase inhibition and cell growth arrest after telomestatin treatment in multiple myeloma. Clin Cancer Res 2004;10:770-6.
25. Heald RA, Modi C, Cookson JC, et al. Antitumor polycyclic acridines. 8.(1) Synthesis and telomerase-inhibitory activity of methylated pentacyclic acridinium salts. J Med Chem 2002;45:590-7.
26. Shammas MA, Shmookler Reis RJ, Akiyama M, et al. Telomerase inhibition and cell growth arrest by G-quadruplex interactive agent in multiple myeloma. Mol Cancer Ther 2003;2:825-33.
27. Read MA, Harrison RJ, Romagnoli B, et al. Structure-based design of selective and potent G quadruplex-mediated telomerase inhibitors. Proc Natl Acad Sci U S A 2001;98:4844-9.
28. Harrison RJ, Cuesta J, Chessari G, et al. Trisubstituted acridine derivatives as potent and selective telomerase inhibitors. J Med Chem 2003;46:4463-76.
29. Gowan SM, Harrison JR, Patterson L, et al. A G-quadruplex-interactive potent small-molecule inhibitor of telomerase exhibiting in vitro and in vivo antitumor activity. Mol Pharmacol 2002;61:1154-62.
30. Skehan P, Storeng R, Scudiero D, et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990;82:1107-12.
31. Dimri GP, Lee X, Basile G, et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci U S A 1995;92:9363-7.
32. Fiebig HH, Burger AM. Human tumor xenografts and explants. In: Teicher BA, editor. Animal models in cancer research. Totowa (NJ): Humana Press, Inc.; 2001. p. 113-37.
33. Workman P, Twentyman P, Balkwill F, et al. United kingdom co-ordinating committee on cancer research (ukcccr) guidelines for the welfare of animals in experimental neoplasia (2nd ed). Br J Cancer 1998;77:1-10.
34. Alley MC, Hollingshead MG, Dykes DJ, Waud WR. Human tumor xenograft models in NCI drug development. In: Teicher BA, Andrews PA, editors. Anticancer drug development guide: preclinical screening, clinical trials, and approval, 2nd ed. Totowa (NJ): Humana Press, Inc.; 2004. p. 125-52.
35. Geran RI, Greenberg NH, MacDonald MM, Schumacher AM, Abbott BJ. Protocols for screening chemical agents and natural products against animal tumors and other biological systems. Cancer Chemother 1972;Rep.3:1-103.
36. Subramaniam V, Li H, Wong M, et al. The RING-H2 protein RNF11 is overexpressed in breast cancer and is a target of Smurf2 E3 ligase. Brit J Cancer 2003;89:1538-44.
37. Weissman AM. Themes and variations on ubiquitinylation. Nature Rev Molec Cell Biol 2001;2:169-78.
38. Dai FP, Perez J, Reszka AP, et al. G-quadruplex interaction of 3,6,9-trisubstituted acridines leads to specific telomerase inhibition, induction of senescence and telomere shortening. Eur J Cancer 2002;38:S90.
39. Grand LC, Han H, Munoz RM, et al. The cationic porphyrin TMPyP4 down-regulates c-myc and human telomerase reverse transcriptase expression and inhibits tumor growth in vivo. Molec Cancer Ther 2002;1:566-73.
40. Guo C, Geverd D, Liao R, Hamad N, Counter CM, Price DT. Inhibition of telomerase is related to the life span and tumorigenicity of human prostate cancer cells. J Urol 2001;166:694-8.
41. Nur-E-Kamal A, Li TK, Zhang A, Qi H, Hars ES, Liu LF. Single-stranded DNA induces ataxia telangiectasia mutant (ATM)/p53-dependent DNA damage and apoptotic signals. J Biol Chem 2003;278:12475-81.
42. Izbicka E, Nishioka D, Marcell V, et al. Telomere-interactive agents affect proliferation rates and induce chromosomal destabilization in sea urchin embryos. Anticancer Drug Des 1999;14:355-65.
43. Incles CM, Schultes CM, Kempski H, Koehler H, Kelland LR, Neidle S. A G-quadruplex telomere targeting agent produces p16-associated senescence and chromosomal fusions in human prostate cancer cells. Mol Cancer Ther 2004;3:1201-6.
44. Leonetti C, Amodei S, D'Angelo C, et al. Biological activity of the G-quadruplex ligand RHPS4 (3,11-difluoro-6,8,13-trimethyl-8H-quino[43,2-kl] acridinium methosulfate) is associated with telomere capping alteration. Mol Pharmacol 2004;66:1138-46.
45. Smith CD, Blackburn EH. Uncapping and deregulation of telomeres lead to detrimental cellular consequences in yeast. J Cell Biol 1999;145:203-14.
46. Miller WH, Schipper HM, Lee JS, Singer J, Waxman S. Mechanisms of action of arsenic trioxide. Cancer Res 2002;62:3893-903.
47. Faraoni I, Turriziani M, Masci G, et al. Decline in telomerase activity as a measure of tumor cell killing by antineoplastic agents in vitro. Clin Cancer Res 1997;3:579-85.
48. Ishibashi T, Lippard SJ. Telomere loss in cells treated with cisplatin. Proc Natl Acad Sci U S A 1998;95:4219-23.
49. Burger AM, Double JA, Newell DR. Inhibition of telomerase activity by cisplatin in human testicular cancer cells. Eur J Cancer 1997;33:638-44.
50. Mo Y, Gan Y, Song S, et al. Simultaneous targeting of telomeres and telomerase as a cancer therapeutic approach. Cancer Res 2003;63:579-85.